bioAffinity Technologies, Inc.
Financial highlights
| Metric | FY December 31, 2025 | FY December 31, 2024 | FY December 31, 2023 | FY December 31, 2022 | FY December 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $6.2M | $9.4M | $7.9M | $6.9M | — |
| Gross profit | — | — | — | $4,336 | — |
| Operating income | -$10.6M | -$9.0M | -$8.0M | -$4.0M | -$2.2M |
| Operating expenses | $16.7M | $18.3M | $10.5M | $4.0M | $2.2M |
| Cost of revenue | — | — | — | $467 | — |
| Cash from operations | -$9.3M | -$7.3M | -$6.0M | -$4.1M | -$2.0M |
| Capital expenditure | $60,568 | $79,083 | $22,902 | $219,987 | — |
| Free cash flow | -$9.4M | -$7.3M | -$6.1M | -$4.3M | — |
| Total assets | $11.0M | $6.5M | $8.2M | $12.2M | $1.5M |
| Total liabilities | $3.7M | $3.9M | $3.4M | $1.1M | $13.2M |
Shares outstanding 4.5M · Free float 93.7%
Annual filing data through FY ended December 31, 2025; float as of June 27, 2026.